Knowledge Hub

Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets Expected To Grow At CAGR Of 3.3% Between Years 2014-2021

Press Release   •   Nov 30, 2016 05:44 EST

GBI Research, the leading business intelligence provider, has released its latest research, ""Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2021 Novel IL-6 and JAK Inhibitors to Stimulate Moderate Growth Despite Brand Erosion of Blockbuster Anti-TNFs"", which provides in-depth analysis of Rheumatoid Arthritis (RA) market within the Asia-Pacific (APAC) market covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2014, along with market forecast until 2021. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.

The value of the RA market in the APAC region amounted to an estimated $5.6 billion in 2014 and is expected to register a Compound Annual Growth Rate (CAGR) of 3.3% to reach $6.9 billion by 2021. The key drivers for growth in the APAC market include: the increasing prevalent population and the anticipated market launch of promising pipeline candidates. The late-stage pipeline which has a potential to stimulate growth during the forecast period include interleukin (IL)-6 inhibitors Sanofi/Regeneron’s sarilumab, Johnson & Johnson/GlaxoSmithKline’s [J&J/GSK’s] sirukumab, small molecules (four janus kinase [JAK] inhibitors: Eli Lilly/Incyte’s baricitinib, Loss of patent exclusitivity of major second-line biologic anti-TNF during such as Enbrel, Remicade and Humira by the end of the forecast period is the major barrier for growth in the RA market size in the APAC markets. Preference for less expensive alternatives to branded medicines, such as biosimilars and other alternate therapies is another major barrier in cost-conscious APAC markets, India and China.

View Report At


  • The report analyzes treatment usage patterns, drug types available and pipeline and market forecasts for RA. It covers and includes
  • A brief introduction to RA, including the disease’s pathophysiology, risk factors, diagnosis and an overview of pharmacotherapy and treatment algorithms.
  • In-depth analysis of the drug combinations used in the treatment of RA, including analyses of their safety, efficacy, and place in the disease treatment algorithm, as well as a heat map comparing the drug combinations in terms of safety and efficacy
  • A comprehensive review of the pipeline for OC therapies, including individual analysis of a number of late-stage pipeline drugs that have the potential to enter the market in the forecast period; the pipeline is analyzed on the basis of phase distribution, molecule type and molecular target, and route of administration
  • Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, and trial duration, and program failure rate analyses for each molecule type and mechanism of action
  • Multi-scenario forecast market data to 2021, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and the changes in disease epidemiology across the APAC markets
  • Discussion of the drivers and barriers for market growth
  • In-depth analysis of licensing and co-development deals involving drugs indicated in RA, including an outline of the key deals

Reasons to buy

  • Primarily, the report will allow clients to gain a strong understanding of RA, helping to identify and clarify market opportunities and the competitive environment. It will also allow you to
  • Understand the RA pipeline and the key trends in the current product development landscape
  • Observe detailed profiles for the promising pipeline products, including revenue forecasts, and gain an insight into how they are likely to compete in the market, and what their main competitors will be
  • Follow the trends in RA clinical trial size and duration in relation to industry averages and assess the potential risk of future developmental programs for RA therapeutics, depending on the mechanism of action, by considering the recorded clinical trial failure rates
  • Observe the potential growth patterns expected for the RA market over the forecast period, and identify which countries are expected to make the biggest contribution to this growth.

Download Sample copy of this Report at :

Table of Contents

1 Table of Contents

1 Table of Contents 5

1.1 List of Tables 8

1.2 List of Figures 8

2 Introduction 10

2.1 Disease Introduction 10

2.2 Symptoms 11

2.3 Etiology 11

2.4 Pathophysiology 11

2.5 Diagnosis 12

2.5.1 Physical Examination 12

2.5.2 Blood Tests 12

2.5.3 1987 Rheumatoid Arthritis Classification 13

2.5.4 2010 ACR-EULAR Classification Criteria for Rheumatoid Arthritis 13

2.6 Epidemiology 14

2.7 Co-morbidities and Complications 14

2.8 Disease Progression 15

2.9 Pharmacotherapy Algorithm 15

2.10 Treatment Options 16

2.10.1 Pharmacological 17

2.10.2 Methotrexate 17

2.10.3 Hydroxychloroquine 17

2.10.4 Leflunomide 17

2.10.5 Sulfasalazine 17

2.10.6 Cyclosporine 18

2.10.7 Prograf (tacrolimus) 18

2.10.8 Xeljanz (tofacitinib) 18

2.11 Other Non-biologics 18

2.11.1 Non-steroidal Anti-inflammatory Drugs 18

2.11.2 Painkillers 18

2.11.3 Glucocorticoids 18

2.12 Biologic Disease-Modifying Anti-rheumatic Drugs 19

2.12.1 Tumor Necrosis Factor Alpha Inhibitors 19

2.12.2 Interleukin Inhibitors 19

2.12.3 Other Biologics that Target B- and T-Cell Antigens 19

2.13 Disease Scoring Methods for Measuring Treatment Efficacy 20

2.13.1 Radiographic Progression 20

2.13.2 Clinical Disease Activity Index and Simplified Disease Activity Index 20

2.13.3 Disease Activity Score-28 20

2.13.4 American College of Rheumatology 20

2.13.5 Health Assessment Questionnaire 20

3 Marketed Products 21

3.1 Overview 21

3.2 Small-Molecule Disease-Modifying Anti-rheumatic Drugs 21

3.2.1 Methotrexate-Based Products 21

3.2.2 Xeljanz (tofacitinib) – Pfizer 22

3.3 Biologic Disease-Modifying Anti-rheumatic Drugs 23

3.3.1 Remicade (infliximab) – Johnson & Johnson, Merck 23

3.3.2 Humira (adalimumab) – AbbVie 24

3.3.3 Enbrel (etanercept) – Amgen, Pfizer and Takeda Pharmaceutical 25

3.3.4 Rituxan (rituximab) – Genentech, Biogen IDEC 27

3.3.5 Orencia (abatacept) – Bristol-Myers Squibb 28

3.3.6 Simponi (golimumab) – Johnson & Johnson, Merck 29

3.3.7 Cimzia (certolizumab pegol) – UCB 30

3.3.8 Kineret (anakinra) – Swedish Orphan Biovitrum 31

3.3.9 Actemra (tocilizumab) – Roche 32

3.3.10 Comparative Safety and Efficacy 33

3.4 Unmet Need 36

4 Product Pipeline 37

4.1 Overview 37

4.2 Pipeline Distribution by Phase of Development, Molecule Type, Route of Administration and Novelty 37

4.3 Pipeline Distribution by Mechanism of Action 39

4.3.1 Cytokine Inhibitors 41

4.3.2 B- and T-cells 42

4.3.3 Intracellular Kinases 43

4.4 Clinical Trial Analysis 44

4.4.1 Overall Attrition Rate 44

4.4.2 Attrition Rate by Phase, Molecule Type and Target 45

4.4.3 Average Clinical Trial Size by Molecule Type 46

4.4.4 Average Clinical Trial Size by Mechanism of Action 49

4.4.5 Average Clinical Trial Duration per Molecule Type by Product 50

4.4.6 Average Clinical Trial Duration per Mechanism of Action by Product 52

4.4.7 Primary and Secondary Endpoints 53

4.4.8 Summary 54

4.5 Promising Pipeline Drugs 54

4.5.1 Baricitinib – Eli Lilly 54

4.5.2 Sarilumab – Regeneron Pharmaceuticals/Sanofi 55

4.5.3 Sirukumab – Johnson & Johnson 56

4.5.4 Decernotinib – Vertex Pharmaceuticals 56

4.5.5 Masitinib 57

4.5.6 Denosumab 57

4.6 Comparative Heat Map 58 is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.